



The Clinical Utility of Cell-Free DNA Measurement in
Differentiated Thyroid Cancer:
Fussey, Jonathan M.; Bryant, Jennifer L.; Batis, Nikolaos; Spruce, Rachael J.; Hartley,






Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Fussey, JM, Bryant, JL, Batis, N, Spruce, RJ, Hartley, A, Good, JS, McCabe, CJ, Boelaert, K, Sharma, N &
Mehanna, H 2018, 'The Clinical Utility of Cell-Free DNA Measurement in Differentiated Thyroid Cancer: A
Systematic Review', Frontiers in Oncology, vol. 8, no. APR, 132. https://doi.org/10.3389/fonc.2018.00132,
https://doi.org/10.3389/fonc.2018.00132
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Fussey Jonathan M., Bryant Jennifer L., Batis Nikolaos, Spruce Rachael J., Hartley Andrew, Good James S., McCabe Christopher J.,
Boelaert Kristien, Sharma Neil, Mehanna Hisham, The Clinical Utility of Cell-Free DNA Measurement in Differentiated Thyroid Cancer: A
Systematic Review, Frontiers in Oncology, 8, 2018, pg. 132, https://www.frontiersin.org/article/10.3389/fonc.2018.00132,
10.3389/fonc.2018.00132, ISSN: 2234-943X
Published in Frontiers in Oncology on 30/04/2018
DOI: 10.3389/fonc.2018.00132
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
April 2018 | Volume 8 | Article 1321
SyStematic Review
published: 30 April 2018
doi: 10.3389/fonc.2018.00132
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Mitali Dandekar, 
Pranidhana Speciality Ear Nose 
Throat & Head Neck Clinic, India
Reviewed by: 
Markus Brunner, 
Medizinische Universität Wien, 
Austria  
Sandro J. Stoeckli, 
Kantonsspital St. Gallen, 
Switzerland
*Correspondence:




This article was submitted to 
Head and Neck Cancer, 






Fussey JM, Bryant JL, Batis N, 
Spruce RJ, Hartley A, Good JS, 
McCabe CJ, Boelaert K, Sharma N 
and Mehanna H (2018) The 
Clinical Utility of Cell-Free DNA 
Measurement in Differentiated 
Thyroid Cancer: 
A Systematic Review. 
Front. Oncol. 8:132. 
doi: 10.3389/fonc.2018.00132
the clinical Utility of cell-Free DNa 
measurement in Differentiated 
thyroid cancer: a Systematic Review
Jonathan M. Fussey1*, Jennifer L. Bryant1, Nikolaos Batis1, Rachael J. Spruce1, Andrew 
Hartley2, James S. Good3, Christopher J. McCabe4, Kristien Boelaert4, Neil Sharma1† and 
Hisham Mehanna1†
1 School of Cancer Sciences, Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, 
United Kingdom, 2 Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, United Kingdom, 
3 Department of Oncology, University Hospital Birmingham, Birmingham, United Kingdom, 4 College of Medical and Dental 
Sciences, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom
Background: Cell-free DNA (cfDNA) can be detected in the circulation of healthy indi-
viduals, but is found in higher concentrations in cancer patients. Furthermore, mutations 
in tumor cells can be identified in circulating DNA fragments. This has been the subject of 
significant interest in the field of cancer research, but little has been published in thyroid 
cancer.
Objectives: To assess all available evidence on the use of circulating cfDNA in the 
diagnosis, management and surveillance of patients with differentiated thyroid cancer, 
and collate it into a systematic review to guide future research.
methods: A comprehensive literature search on the measurement of cfDNA in thyroid 
cancer was undertaken, and results from relevant studies collated into a systematic 
review.
Results: Nine studies were identified, with varying methodologies and findings. Key 
techniques and findings are summarized.
conclusion: There is limited but promising evidence that somatic mutations in thyroid 
cancer can be detected in circulating cfDNA and are associated with more advanced 
disease. Further research is required to develop a clinically useful tool based on cfDNA 
to improve the management of thyroid cancers.
Keywords: thyroid cancer, DNa, cell-free, cell-free DNa, circulating DNa, cell-free systems
iNtRODUctiON
Rationale
Differentiated thyroid cancer (DTC) accounts for around 1% of all human cancers (1), and rates of 
diagnosis have been increasing in recent years, in part due to improving imaging techniques (2). 
Although survival rates in DTC are very good, there remains a subset of patients in whom the cancer 
behaves more aggressively and requires more aggressive management and follow-up. Distinguishing 
between these patients and those with indolent DTC remains a challenge. Management of DTC 
includes thyroidectomy with or without postoperative radioiodine ablation and long-term thyroid 
stimulating hormone suppression (3). Surveillance of DTC patients following treatment relies in 
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part on measurement of serum thyroglobulin levels. However, 
25–30% of DTC patients have thyroglobulin antibodies (4), 
which limit the usefulness of this test.
Cell-free DNA (cfDNA) was first described in 1948 (5). Tumor 
DNA fragments are released into the circulation as a result of 
necrosis and apoptosis (6), or secretion by cancer cells. Modern 
polymerase chain reaction (PCR) and sequencing techniques 
allow identification of nucleic acids in peripheral blood samples, 
and thus represent an opportunity for the development of novel 
diagnostic and surveillance tests in cancer patients. Indeed, in 
other cancers, the measurement of cfDNA has been shown to be 
a feasible clinical tool (7, 8).
Many somatic mutations have been described in DTC, and 
some have been shown to predict more aggressive tumor behavior 
(9, 10). For example, a point mutation in the BRAF gene resulting 
in the substitution of valine for glutamate at codon 600 can be 
identified in 24.7–74.7% of papillary thyroid cancers depending 
on subtype (10). A large meta-analysis demonstrated statistically 
significant correlation between BRAFV600E and tumor size, lymph 
node metastasis, multifocality, extrathyroid extension, and clinical 
stage (10).
Objective
With the current challenges in risk stratification and surveillance 
of thyroid cancer patients, the possibility of detecting circulat-
ing tumor cfDNA represents a promising potential advance in 
the management of DTC. The objective of this review was to 
systematically review the current evidence on the subject of 
cfDNA measurement in DTC patients.
Research Question
Can circulating cell-free tumor DNA be used to aid the diagnosis, 
risk stratification, and surveillance of patients with DTC?
mateRiaLS aND metHODS
Study Design and Search Strategy
A preliminary search of the Cochrane library was performed to 
identify pre-existing reviews on the subject, but none was found. 
A comprehensive search of the published literature was then per-
formed using Medline. Search terms and Boolean operators used 
were “cell free systems” OR “cell free DNA” OR “cell free nucleic 
acids” OR “cell free RNA” OR “nucleic acids” OR “circulating 
DNA” AND “adenocarcinoma, papillary” OR “adenocarcinoma, 
follicular” OR “thyroid neoplasm.” Filters were used to identify 
articles concerning humans and published in the last 15 years. 
No language restrictions were applied. Titles and abstracts were 
screened for relevance according to a previously developed review 
protocol. Reference lists were manually searched for relevant arti-
cles not identified by the initial search. Finally, a generic Internet 
search engine was used to further maximize the search yield.
Participants, interventions, comparators
All articles concerning the measurement of cfDNA in adult thy-
roid cancer patients were considered. Studies describing the use 
of cfDNA for diagnosis, prognosis, or surveillance were included. 
Articles that did not include patients with DTC were excluded, 
as were review articles and those with fewer than 10 subjects. No 
restrictions were placed on study design, outcome measures, or 
study population.
Systematic Review Protocol and Data 
extraction
Data were extracted from included studies and collated using a 
pro forma in Microsoft Excel (Redmond, WA, USA). Categories 
for data extraction included study design; objective for cfDNA 
measurement; demographic details of subjects; tumor histology 
and characteristics; method of cfDNA measurement; format of 
results reporting and quantitative and qualitative results.
Data analysis
Due to the heterogeneity of the data reported by different authors 
and the variation in outcome measures used, statistical meta-
analysis was not possible. Therefore, following data extraction, 
results were grouped and reported according to outcome measure.
ReSULtS
Search Results and Study Selection
The initial Medline search as described above produced 2,680 
titles. This was reduced to 1,486 titles by applying filters for 
human studies published in the last 15 years. Of these, 1,483 could 
be excluded based on title and abstract alone due to irrelevance 
to the review objective. This left three articles for inclusion. In 
addition to this, a manual search of reference lists identified five 
further articles, and one further article and an unpublished thesis 
were identified using Internet search engines. This resulted in nine 
articles for inclusion. Figure  1 shows the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses flowchart.
characteristics of included Studies
The nine included studies were published between 2006 and 
2017. Eight of them were peer-reviewed publications (11–18) 
and one was a scientific thesis published on the Electronic 
Thesis and Dissertation Repository (19). Seven studies were 
prospective, and two were retrospective. There were a total of 
994 patients in the combined studies, with an average of 110 
(range 28–200) per study. Of these, 633 had confirmed DTC. 
Three studies included healthy subjects as controls, and seven 
included patients with benign thyroid disease. The studies were 
heterogeneous in their aims and objectives, with some setting out 
to use cfDNA measurement as a diagnostic tool, some investigat-
ing its utility as a prognostic marker, and others simply assessing 
feasibility of cfDNA measurement in thyroid cancer. There was 
also significant variation in the outcome measures reported, so 
meta-analysis was not appropriate. General study characteristics 
are represented in Table 2.
cfDNa measurement
All studies described the extraction of cfDNA in detail. Five 
studies used plasma samples, three used serum samples, and 
one used whole blood. Following DNA extraction, the majority 
FigURe 1 | Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 flow diagram.
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of studies used real-time PCR to identify BRAFV600E. In some 
cases, this was quantitative TaqMan PCR with primers for 
both BRAFV600E and BRAFWT alleles, and in others, digestion of 
wild type alleles was used to reduce contamination by normal 
BRAF from surrounding tissues. In addition, two studies used 
quantitative methylation-specific PCR to identify methylation 
in target genes (14, 17). One study, by Salvianti et al., measured 
the percentage of fragments of differing lengths of the APP gene 
circulating in plasma, in the range of 67–180 base pairs. Using 
quantitative real-time PCR, they calculated the quantity of the 
longer and shorter fragments in plasma, then calculated the ratio 
between the absolute concentration of the longer and shorter 
fragments to give a cfDNA integrity index (18). They then meas-
ured this in thyroid cancer patients and healthy individuals to 
test the hypothesis that longer strand cfDNA can be used as a 
biomarker for tumor presence.
Three studies measured cfDNA in healthy individuals. Zane 
et  al. found a statistically significantly lower level of cfDNA in 
healthy individuals compared with thyroid cancer patients 
(median levels 5.14 and 22.54  ng/ml, respectively, p <  0.0001) 
(17). Pupilli et  al. found a statistically significantly elevated 
percentage of circulating BRAFV600E mutated allele over wild type 
allele in patients with Thy3 (18.7%) and Thy4 and Thy5 (27.1%) 
cytology compared with healthy individuals (1.7%) (11). Salvianti 
et al. found both a lower level of cfDNA in healthy individuals, 
and a lower cfDNA integrity index when compared with patients 
with thyroid nodules of any cytology (18).
Seven of the nine studies included patients with benign thy-
roid disease. Two of them found no circulating BRAFV600E in their 
benign patients (15, 19), and one was able to show a statistically 
significant difference in circulating BRAFV600E levels between 
those with benign thyroid disease and thyroid cancer (11). 
Pupilli et al. demonstrated a circulating BRAFV600E over BRAFWT 
percentage of 9.9% in patients with benign thyroid disease and 
27.3% in patients with cancer (11).
Overall six studies reported on the presence of the BRAFV600E 
cfDNA mutation in DTC patients, with a combined total of 438 
affected individuals (11, 13, 15–17, 19). Circulating BRAFV600E 
was measured by some authors pre-treatment and by others post-
treatment, and was identified in 10% of these patients overall. Of 
the 302 patients in whom tumor BRAFV600E was measured, 36.8% 
were positive. The proportion of patients with BRAFV600E muta-
tion in the tumor who also had circulating BRAFV600E was 16.5%.
cfDNa as a Diagnostic tool
Pupilli et  al. prospectively measured the percentage of plasma 
BRAFWT and BRAFV600E cfDNA in 38 patients with PTC, 16 with 
benign disease, and 49 healthy individuals (11). They compared 
levels of circulating BRAFV600E with cytology results and with 
final histology. They found that patients with Thy2 cytology had 
a significantly lower percentage of BRAFV600E cfDNA (8.9%) than 
those with Thy4 and Thy5 cytology (27.1%). They also demon-
strated a statistically significantly elevated circulating BRAFV600E 
level in patients with PTC (23.7%) compared with those with 
benign thyroid nodules (9.9%).
Hu et  al. measured methylation of cfDNA, specifically 
focusing on five genes: CALCA, CDH1, TIMP3, DAPK, and 
RARβ2 (14). They retrospectively compared methylation levels 
in peripheral blood samples taken at the time of nodule assess-
ment between thyroid cancer patients and those with benign 
thyroid nodules. When all five genes were considered, they 
achieved a diagnostic sensitivity of 68%, and a specificity of 
95%, with a preoperative diagnostic accuracy of 77%. They also 
looked at a subset of patients with indeterminate cytology, and 
found that none of the four patients who were eventually found 
to have benign disease had positive cfDNA methylation levels, 
taBLe 1 | Quality Assessment of Diagnostic Accuracy Studies-2 checklist 
[adapted from Whiting et al. (20)].
Domain 1: Patient Selection
Was a consecutive or random sample of patients enrolled? (Yes/No/Unclear)
Was a case-control design avoided? (Yes/No/Unclear)
Did the study avoid inappropriate exclusions? (Yes/No/Unclear)
Could the selection of patients have introduced bias? Risk:  
Low/High/Unclear
Domain 2: index test(s) (complete for each index test used)
Were the index test results interpreted without knowledge of the reference 
standard? (Yes/No/Unclear)
If a threshold was used, was it pre-specified? (Yes/No/Unclear)
Could the conduct or interpretation of the index test have introduced bias? Risk: 
Low/High/Unclear
Domain 3: Reference Standard
Is the reference standard likely to correctly classify the target condition? (Yes/No/
Unclear)
Were the reference standard results interpreted without knowledge without 
knowledge of the results of the index test? (Yes/No/Unclear)
Could the reference standard, its conduct, or its interpretation have introduced 
bias? Risk: Low/High/Unclear
Domain 4: Flow and timing
Was there an appropriate interval between index test(s) and reference standard? 
(Yes/No/Unclear)
Did all patients receive a reference standard? (Yes/No/Unclear)
Did all patients receive the same reference standard? (Yes/No/Unclear)
Were all patients included in the analysis? (Yes/No/Unclear)
Could the patient flow have introduced bias? Risk: Low/High/Unclear
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whereas 8 of the 11 patients (73%) who were later found to have 
cancer had elevated cfDNA methylation levels. Salvianti et al. 
were able to demonstrate a statistically significant difference in 
cfDNA integrity index between those with Thy2 nodules and 
those with Thy 3 and Thy4/5 nodules (0.67, 0.83, 1.02, respec-
tively, p < 0.001) (18).
cfDNa as a marker of advanced 
Disease
Several of the studies investigated the potential usefulness 
of cfDNA measurement in the identification of patients with 
advanced locoregional or metastatic disease. Kim et  al. were 
only able to identify BRAFV600E cfDNA in 3 of 72 PTC patients, 
but all three of them had lateral neck node metastasis and 
lung metastasis (15). They therefore postulated that circulat-
ing BRAFV600E might have a role in predicting lung metastasis. 
Patel investigated the role of circulating BRAFV600E in predicting 
stage of disease in a sample of six patients, but found no sta-
tistically significant association between detectable BRAFV600E 
cfDNA and primary tumor T classification, nodal metastasis, or 
extrathyroidal extension (19). Similar methods of DNA extrac-
tion were used by both authors, which suggest a statistical cause 
for divergent results.
cfDNa as a marker for monitoring of 
Disease Recurrence
Four studies examined the feasibility of the use of cfDNA for 
monitoring of disease recurrence in thyroid cancer patients. 
Hu et  al. retrospectively measured cfDNA methylation levels 
of a five-gene panel at post-treatment visits in patients being 
followed up after treatment for DTC. They correctly identi-
fied 70% of those with proven recurrence by gold standard 
techniques including radioiodine body scan, tissue biopsy and 
stimulated thyroglobulin, and 79% of those with no evidence 
of recurrence (14). Pupilli et al. found a statistically significant 
drop in BRAFV600E cfDNA levels following treatment, with 71% 
of patients who were preoperatively positive for circulating 
BRAFV600E becoming negative following treatment (12). They 
suggest that it could be a useful tool in surveillance post-
treatment, but warned that further research is required. Cradic 
et al. found that patients with detectable circulating BRAFV600E 
following treatment had a relative risk of 2.55 (p <  0.04) of 
having recurrent disease at the time of blood draw compared 
with those with only BRAFWT detected in peripheral blood 
(13). Salvianti et  al. measured plasma cfDNA integrity index 
in 17 patients 3–6  months following surgery with or without 
radioiodine ablation, and found a lower index post treatment 
(0.57) than before treatment (0.87, p = 0.35) (18).
Risk of Bias and Quality assessment
All studies were assessed for quality and risk of bias according 
to the modified Quality Assessment of Diagnostic Accuracy 
Studies checklist (20) (Table 1). All papers were deemed to have 
a low overall risk of bias, however, only one explicitly described 
consecutive patient recruitment, and only three described a pre-
specified threshold for a positive result.
DiScUSSiON
Summary of main Findings
This review highlights the potential usefulness of cfDNA in 
thyroid cancer patients, and therefore justifies further research 
given the relative lack of evidence compared with other cancers. 
There has been significant interest in cfDNA in other cancers over 
the last 20  years, and it has been studied in breast, colorectal, 
pancreatic, and ovarian cancers, as well as brain tumors and 
melanoma (8, 21–25).
The vast majority of the existing evidence relates to the 
measurement of BRAFV600E cfDNA. This is understandable as 
BRAFV600E is the commonest and most investigated somatic 
mutation in DTC (26), and would therefore be a useful marker if 
it could be reliably detected in the circulation.
The BRAFV600E mutation has been investigated in a number 
of human cancers, and while it is most commonly expressed in 
melanoma and thyroid cancer, circulating BRAFV600E has also 
been found to be detectable in lung cancers (27). There is some 
evidence that the BRAFV600E mutation in thyroid cancer is associ-
ated with more advanced disease, with increased likelihood of 
nodal and distant metastasis (28, 29).
While the majority of research in thyroid cancer cfDNA has 
focused on PCR identification of specific point mutations in 
circulating DNA, two studies have measured methylation of 
specific genes in cfDNA. Methylation is argued to be a more 
reliable marker due to its relative stability in cfDNA compared 
with point mutations, and the fact that there are a wide variety of 
mutations implicated in each cancer type, each with a relatively 
low frequency (30).
taBLe 2 | General study characteristics.
Reference year of 
publication
Study design No. of 
patients
cfDNa measurement Key findings
Pupilli et al. (11) 2013 Prospective 103 Plasma cfDNA BRAFV600E Percentage of BRAFV600E significantly higher in  
those with PTC. Significant drop after treatment
Chuang et al. (12) 2010 Prospective 28 Serum cfDNA BRAFV600E Of those with tumor BRAFV600E, 60% also had  
detectable cfDNA BRAFV600E
Cradic et al. (13) 2009 Prospective 193 Circulating BRAFV600E BRAFV600E detected in blood of 11.6% of DTC  
patients and correlated with active disease
Hu et al. (14) 2006 Retrospective 92 Serum cfDNA methylation various genes cfDNA methylation of β-actin, CALCA, CDH1,  
TIMP3, DAPK, RARβ2 in 95% DTC with 96% PPV
Kim et al. (15) 2015 Retrospective 77 Plasma cfDNA BRAFV600E cfDNA BRAFV600E mutation only identified in 4.2%  
of PTC patients, but all of these had lung metastasis
Kwak et al. (16) 2013 Prospective 94 Serum cfDNA BRAFV600E Unable to identify BRAFV600E mutation in the serum  
of any individual with PTC
Zane et al. (17) 2013 Prospective 200 Plasma cfDNA BRAFV600E and methylation 
of SLC5A8 and SLC26A4
Higher levels of cfDNA in DTC patients, but unable  
to isolate BRAFV600E in circulation in any patients
Salvianti et al. (18) 2017 Prospective 146 Plasma cfDNA and APP gene integrity 
index
Correlation between cfDNA integrity index and cytological 
evidence of thyroid cancer. Reduction in integrity  
index following treatment
Patel (19) 2015 Prospective 61 Plasma cfDNA BRAFV600E cfDNA BRAFV600E in 23% of those with PTC and none  
of those with benign nodules. Levels fell post-treatment
PTC, papillary thyroid carcinoma; DTC, differentiated thyroid carcinoma; PPV, positive predictive value; cfDNA, cell-free DNA.
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Of the studies that reported overall detection rates of BRAFV600E 
in circulating cfDNA, the average detection rate in patients with 
DTC was 10%. This increased to 19.3% when patients with non-
BRAFV600E tumors were excluded. These relatively low levels may 
be due to the fact that tumors of all stages were included, and 
shedding of tumor DNA into the circulation is likely to occur at 
low levels in early stage disease and therefore may not be detect-
able with current techniques. The most promising evidence for 
the potential use of cfDNA as a diagnostic tool in thyroid cancer 
comes from Pupilli et al., who demonstrated a significantly higher 
proportion of BRAFV600E cfDNA in patients with PTC than those 
with benign nodules, and a higher proportion in those with suspi-
cious cytology than those with benign cytology (11). They suggest 
that the use of assay reagents with inadequate sensitivity could 
explain the variation in detection rates amongst other researchers. 
Their findings point to the feasibility of the developing a tool 
to help distinguish between benign and malignant nodules in 
patients with indeterminate cytology, or those with large nodules 
in whom a representative cytology sample is difficult.
It has been shown in other cancers that cfDNA levels correlate 
with stage of disease, and the rate of release into the circula-
tion of cfDNA corresponds to primary tumor size (31, 32). In 
fact, one study has suggested that BRAFV600E cfDNA levels are 
associated with nodal and distant metastasis in PTC (15), and a 
meta-analysis has demonstrated advanced clinical stage associ-
ated with BRAFV600E mutation (10). This raises the potential of 
a peripheral detection of BRAFV600E as a non-invasive marker of 
aggressive disease. cfDNA also represents a promising target for 
the development of new methods of detecting disease recurrence 
following treatment. Currently, surveillance depends on ultra-
sonography of the neck, and serial thyroglobulin measurement, 
which is hindered by the presence of antibodies in 25–30% of 
patients (4). Researchers studying other cancers have demon-
strated that a drop in the level of total cfDNA during treatment 
can predict response to therapy (21), and this was also the case in 
the study that measured pre- and post-treatment levels in thyroid 
cancer (11).
Limitations
Although cfDNA research is a rapidly evolving field, there is 
still a limited amount of evidence available relating to its use 
in thyroid cancer. The small number of published studies is a 
significant limitation on the ability of this systematic review to 
answer the research question.
There is also difficulty in comparing findings of studies on 
cfDNA in general due to various methods of DNA isolation and 
detection, and results reporting, which is also the case when 
considering the evidence in thyroid cancer. The use of serum and 
plasma measurements are described, and some authors report 
percentage of patients with detectable levels, some report quanti-
tative levels and others report ratio of mutant to wild type alleles.
The majority of research to date has focused on the detection 
of one specific mutation in cfDNA—BRAFV600E. While BRAF is 
the most commonly mutated gene in sporadic PTC, with a rate of 
18–87% (33, 34), The Cancer Genome Atlas project has shown the 
genomic landscape of PTC to be much more complex, with a num-
ber of significantly mutated genes (35). While the use of cfDNA for 
post-treatment surveillance has the advantage of the availability 
of somatic mutations in the resected tumor, if it were to become 
a sensitive diagnostic tool, expanded panels of genetic mutations 
would need to be detected to avoid false negatives in BRAF nega-
tive caners. Furthermore, there has been significant variation in the 
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reported rates of detection of cfDNA in thyroid cancer patients. 
This could be due to differences in tumor expression of BRAFV600E 
in different populations, differences in ability to detect cfDNA 
with different techniques, or non-representative study popula-
tions skewed by over-representation of early or advanced tumors. 
Further improvements and standardization in methodology are 
also needed. The use of a cfDNA integrity index as described by 
Salvianti et al. (18), which qualitatively evaluates cfDNA as well 
as measuring absolute concentrations, may prove to be a valuable 
addition to other biomarkers using cfDNA in thyroid cancer.
conclusion
Cell-free DNA measurement is an area of particular interest in 
the field of thyroid cancer management due to the current dif-
ficulties in diagnosis, identification of high-risk patients, and 
post-treatment surveillance. Early findings, although heteroge-
neous, provide promising insights and certainly warrant further 
investigation. A deeper understanding of how and when tumor 
DNA is shed from primary tumors and metastases into the circu-
lation, and the development of more sensitive cfDNA assays are 
likely to improve progress toward the ultimate goal of a clinically 
useful test.
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